Aspire Biopharma Holdings (ASBP) risk factors, FY2024 10-K

Risks related to our Business

1. 01Aspire has a limited operating history upon which investors can evaluate Aspire’s performance, and accordingly, Aspire’s prospects must be considered in light of the risks that any new company encounters
2. 02Aspire has incurred net losses in every year since its inception and anticipates that it will continue to incur substantial and increasing net losses in the foreseeable future, especially if Aspire faces difficulties in obtaining capital
3. 03Aspire will require substantial additional financing to achieve its goals, and a failure to obtain this necessary capital when needed could force Aspire to delay, limit, reduce or terminate its product development or commercialization efforts
4. 04Aspire may implement new lines of business or offer new products and services within existing lines of business
5. 05Aspire relies on other companies to provide components and services for its product candidates
6. 06Aspire relies on various intellectual property rights, including trademarks, in order to operate its business
7. 07Instaprin Pharmaceuticals’ former Chief Executive officer, Donald A. Milne III, was convicted, on a conspiracy to commit securities fraud charge
8. 08Aspire’s success depends on the experience and skill of the board of directors, its executive officers and key employees. If it is not successful in attracting and retaining highly qualified personnel, Aspire may not be able to successfully implement its business strategy
9. 09Although dependent on certain key personnel, Aspire does not have any key person life insurance policies on any such people
10. 10Damage to Aspire’s reputation could negatively impact its business, financial condition and results of operations
11. 11Aspire’s business could be negatively impacted by cyber security threats, attacks and other disruptions
12. 12Security breaches of confidential customer information, in connection with Aspire’s electronic processing of credit and debit card transactions, or confidential employee information may adversely affect Aspire’s business as we gain access to such information
13. 13Aspire’s internal computer systems, or those used by third party contractors or consultants, may fail or suffer security breaches
14. 14Aspire operates in a highly regulated environment, and if Aspire is found to be in violation of any of the federal, state, or local laws or regulations applicable to it, Aspire’s business could suffer
15. 15Our business, operations, financial position and clinical development plans and timelines, could be materially adversely affected by the continuing military action in Ukraine and the war between Israel and Hamas
16. 16International trade disputes, including U.S. trade tariffs and retaliatory tariffs, could adversely impact our business
17. 17Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations
18. 18We are dependent on a limited number of suppliers and service providers which subjects our business and results of operations to risks of supplier business interruptions

Risks related to our Products and Their Development

1. 19Current Development Status of Aspirin Product
2. 20Current Development Status of Other Products
3. 21Semaglutide: Aspire’s scientists are in the final phases of developing a working formulation for a sublingual semaglutide product. The timeline to market will be similar to that of testosterone, above, as semaglutide is not likely a candidate for fast-track approval
4. 22Aspire’s business is highly dependent on the success of its lead product candidate, high-dose sublingual aspirin, which will require significant additional clinical testing before Aspire can seek regulatory approval and potentially launch commercial sales
5. 23In addition, even if the trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and we may need to conduct additional trials before we submit applications seeking regulatory approval of our product candidates
6. 24Aspire’s product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, if approved, or result in significant negative consequences
7. 25If Aspire encounters difficulties enrolling patients in its clinical trials, Aspire’s clinical development activities could be delayed or otherwise adversely affected
8. 26Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates
9. 27If Aspire fails to develop additional product candidates, its commercial opportunity will be limited
10. 28Aspire is subject to a multitude of manufacturing and supply chain risks, any of which could substantially increase its costs and limit the supply of its product candidates
11. 29Aspire currently has no marketing and sales organization and has no experience in marketing products. If Aspire is unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell its product candidates, Aspire may not be able to generate product revenue
12. 30A variety of risks associated with marketing Aspire’s product candidates internationally could materially adversely affect Aspire’s business
13. 31Aspire faces significant competition from other biotechnology and pharmaceutical companies, and its operating results will suffer if it fails to compete effectively
14. 32Aspire’s employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
15. 33If product liability lawsuits are brought against Aspire, it may incur substantial liabilities and may be required to limit commercialization of Aspire’s product candidates
16. 34Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators
17. 35If Aspire’s third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, Aspire may be liable for damages

Risks Related to Being a Public Company After a Business Combination

1. 36The price of our Common Stock and warrants may fluctuate significantly following the Business Combination and you could lose all or part of your investment as a result
2. 37Your percentage ownership in us may be diluted by future issuances of capital stock, which could reduce your influence over matters on which stockholders vote